Geron Corp Stock Price, News & Analysis

Geron (Nasdaq: GERN) reported inducement equity awards to newly hired employees under Nasdaq Listing Rule 5635(c)(4).

On October 17, 2025 Geron granted awards covering 1,579,500 shares (1,553,000 stock options and 26,500 RSUs). On October 20, 2025 Geron granted awards covering 1,500,000 shares to one new hire. Options from October 17 carry an exercise price of $1.20; options from October 20 carry an exercise price of $1.27—each equal to the closing price on the grant date.

Options have a 10-year term and vest over 4 years (12.5% at six months, then monthly over 42 months). RSUs vest 25% annually over four years. Awards were granted by the Compensation Committee under Geron’s 2018 Inducement Award Plan.

Geron (Nasdaq: GERN) announced executive leadership transitions on Oct 13, 2025. Andrew Grethlein (EVP, COO) and Jim Ziegler (EVP, CCO) will depart on Oct 15, 2025, with Grethlein moving to a consulting role. Effective Oct 20, 2025, Ahmed ElNawawi is appointed EVP, Chief Commercial Officer to lead U.S. commercial strategy for RYTELO. Three additional senior hires announced: Shantha Tyavanagimatt as SVP, Chief Technical Officer; Dawn Schottlandt as SVP, Investor Relations and Corporate Affairs; and Bryan Ridgell as SVP, Portfolio and Project Management and Chief of Staff (joined Oct 13, 2025).

The appointments emphasize commercial scale-up, technical operations, investor engagement, and portfolio management to support RYTELO commercialization and future portfolio expansion.

Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, has granted equity awards totaling 966,000 shares to sixteen new employees as employment inducements. The awards, granted on September 17, 2025, include 644,000 stock options at $1.27 per share and 322,000 restricted stock units (RSUs).

The stock options have a ten-year term with a 4-year vesting schedule, starting with 12.5% vesting at six months and the remainder over 42 months. RSUs vest 25% annually over four years. These awards were approved under Nasdaq Listing Rule 5635(c)(4) through Geron's 2018 Inducement Award Plan.

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference in Boston, MA. The presentation is scheduled for September 4, 2025.

Investors can access a live webcast of the presentation through Geron's investor relations website at ir.geron.com. The webcast recording will remain available for replay for 30 days after the event.

Geron Corporation (Nasdaq: GERN) has granted equity awards totaling 522,000 shares to eleven new employees as employment inducement. The awards consist of 348,000 stock options at $1.45 per share and 174,000 restricted stock units (RSUs).

The stock options have a ten-year term with a 4-year vesting schedule, starting with 12.5% vesting after six months and the remainder vesting over 42 months. The RSUs vest 25% annually over four years. These awards were granted under Geron's 2018 Inducement Award Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

Geron Corporation (Nasdaq: GERN) has granted stock options to its new President and CEO, Harout Semerjian, as an inducement for employment. The grant includes options to purchase 11 million shares of common stock at $1.30 per share, equal to the closing price on August 7, 2025.

The options are structured in two tranches: 7 million shares vesting over 4 years with 12.5% vesting after 6 months, and 4 million shares vesting over 4 years with 25% vesting after one year. The options have a ten-year term and were granted under Geron's 2018 Inducement Award Plan.

Geron Corporation (Nasdaq: GERN) reported strong Q2 2025 financial results, highlighting $49.0 million in RYTELO® net product revenue, representing a 24% increase from Q1. The company announced the appointment of Harout Semerjian as President and CEO and reported significant commercial progress with over 1,000 ordering accounts.

Key financial metrics include a reduced net loss of $16.4 million ($0.02 per share), compared to $67.4 million in Q2 2024. The company maintains a strong cash position of $432.6 million. The Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis has reached 95% enrollment, with full enrollment expected by year-end 2025.

Geron Corporation (Nasdaq: GERN) has appointed Harout Semerjian as its new President and Chief Executive Officer, effective immediately. Semerjian brings over 30 years of commercial experience in hematology and oncology, including significant leadership roles at Novartis, Ipsen, and GlycoMimetics. He succeeds Dawn Carter Bir, who served as Interim President and CEO since March 2025 and will remain on Geron's Board of Directors.

The appointment comes at a crucial time as Geron focuses on expanding the reach of its product RYTELO and advancing its late-stage pipeline, including the IMpactMF Phase 3 trial in relapsed/refractory myelofibrosis. Semerjian's extensive experience includes leading global commercial operations for key hematology therapies like Gleevec® and KISQALI®.

Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, before market open. The company will host a conference call at 8:00 a.m. Eastern Time to discuss financial results and business highlights.

The announcement will be available through a press release on the company's website, along with a live webcast of the conference call and presentation. The webcast recording will remain accessible on Geron's website for 30 days following the event.